瑞康医药集团股份有限公司（以下简称"公司"、"瑞康医药"）于 2024 年 11 月 7 日召开第五届董事会第十次会议，审议通过了《关于回购公司股份方 案的议案》，同意公司使用银行专项贷款资金及自有资金以集中竞价交易方式回 购公司部分已发行的人民币普通股（A 股），本次回购股份将用于实施员工持股 计划，回购股份的资金总额不低于人民币 10,000 万元（含），不超过人民币 20,000 万元（含），回购股份的价格不超过人民币 4.5 元/股（含），具体回购股份的数 量以回购期限届满或回购完毕时实际回购的股份数量为准，实施期限为董事会审 议通过回购股份方案之日起 12 个月内。具体内容详见公司于 2024 年 11 月 11 日 在巨潮资讯网披露《第五届董事会第十次会议决议的公告》（2024-036）及《关 于回购公司股份方案暨取得金融机构股票回购专项贷款承诺函的公告》（公告编 号：2024-037）、2024 年 12 月 12 日在巨潮资讯网披露《回购报告书》（公告编 号：2024-048）。 根据《上市公司股份回购规则》、《深圳证券交易所上市公司自律监管指引 第 9 号——回购股份》等相关规定，回购期间， ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 2.71% on August 27, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Saily Medical (603716) closed at 33.15, down 8.93% with a trading volume of 484,700 shares and a transaction value of 1.671 billion [1] - Other notable declines included HeLiang China (603122) down 5.15%, YaoYigou (300937) down 5.10%, and Guofa Shares (600538) down 4.98% [1] - The overall net outflow of main funds from the pharmaceutical commercial sector was 543 million, while retail investors saw a net inflow of 361 million [1] Fund Flow Analysis - Jiuzhoutong (600998) had a main fund net inflow of 11.8 million, accounting for 18.23% of its total [2] - Dacilin (603233) saw a main fund net inflow of 29.97 million, representing 15.70% [2] - The overall trend indicates a mixed sentiment with main funds withdrawing while retail investors are actively buying [2]

Core Viewpoint - 瑞康医药发布的2025年中报显示，公司净利润和营业总收入均出现显著下降，反映出其财务表现不佳，且面临较大的经营压力 [1] Financial Performance - 2025年中报显示，营业总收入为35.44亿元，同比下降12.11% [1] - 归母净利润为1816.64万元，同比下降32.35% [1] - 第二季度营业总收入为17.87亿元，同比下降11.23% [1] - 第二季度归母净利润为399.54万元，同比下降65.8% [1] - 毛利率为10.63%，同比下降15.28% [1] - 净利率为0.86%，同比下降0.69% [1] - 每股收益为0.01元，同比下降32.02% [1] Cash Flow and Debt Situation - 每股经营性现金流为0.05元，同比增加642.2% [1] - 货币资金为59.79亿元，同比增加47.94% [1] - 有息负债总额为77.16亿元，同比增加31.67% [1] - 有息资产负债率已达45.51% [4] Accounts Receivable - 应收账款为37亿元，同比下降5.41% [1] - 应收账款与利润的比率已达17943.5% [4] Business Model and Return on Investment - 公司去年的ROIC为1.19%，显示资本回报率不强 [3] - 近10年来中位数ROIC为4.76%，反映出投资回报较弱 [3] - 公司历史上有两次亏损，显示其商业模式较为脆弱 [3]

瑞康医药集团股份有限公司 2025 年半年度财务报告 2025 年半年度财务报告 2025 年 8 月 1 | | | | 二、财务报表 3 | | --- | | 三、公司基本情况 20 | | 四、财务报表的编制基础 21 | | 五、重要会计政策及会计估计 21 | | 六、税项 45 | | 七、合并财务报表项目注释 46 | | 八、研发支出 94 | | 九、合并范围的变更 95 | | 十、在其他主体中的权益 98 | | 十一、政府补助 109 | | 十二、与金融工具相关的风险 110 | | 十三、公允价值的披露 112 | | 十四、关联方及关联交易 114 | | 十五、股份支付 118 | | 十六、承诺及或有事项 119 | | 十七、资产负债表日后事项 119 | | 十八、其他重要事项 120 | | 十九、母公司财务报表主要项目注释 121 | | 二十、补充资料 138 | | 二十一、财务报表之批准 139 | 瑞康医药集团股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的 ...

瑞康医药集团股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：瑞康医药集团股份有限公司 单位：万元 | 资金往来方名称 | 往来方与上 市公司的关 | 上市公司核 算的会计科 | 2025 年期初 往来资金余 | 2025 年半年 度往来累计 | 2025 年半 年度往来 | 2025 年半 年度偿还 | 2025 年半年 度末往来资 | 往来 形成 | 往来性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 联关系 | 目 | 额 | 发生金额 (不含利息) | 资金的利 息(如有) | 累计发生 金额 | 金余额 | 原因 | | | 烟台龙慧康母婴护理有 限公司 | 子公司 | 其他应收款 | 1,102.49 | 505.09 | | 502.67 | 1,104.91 | 借款 | 非经营性往来 | | 吉祥火(烟台)医药科技 有限公司 | 子公司 | 其他应收款 | 18,801.23 | 0.00 | | 0.00 | 18,801.23 | 借款 | 非经营性往来 | ...

瑞康医药集团股份有限公司 2025 年半年度报告全文 2025 年半年度报告 2025 年 8 月 1 瑞康医药集团股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人韩旭、主管会计工作负责人冯芸及会计机构负责人(会计主管 人员)曹庆岩声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 可能存在行业竞争、经营与管理、市场、国家政策等风险，敬请广大投 资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 | 2 | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 6 | | | 第三节 | 管理层讨论与分析 9 | | | 第四节 | 公司治理、环境和社会 | 22 | | 第五节 | 重要事项 | 27 | | 第六节 | 股份变动及股东情况 33 | | | 第七节 | 债券相关情 ...

Group 1 - The company, Ruikang Pharmaceutical, stated that as of August 10, 2025, the total number of shareholders is 72,251 [2]

Core Viewpoint - Ruikang Pharmaceutical Group Co., Ltd. has received a notice from the Jiyang District Supervisory Committee in Jinan, which has changed the detention measures against its director, board secretary, and vice president Li Zhe to a directive for pending investigation [1] Summary by Relevant Sections - **Company Announcement** - Ruikang Pharmaceutical disclosed that the Jiyang District Supervisory Committee has lifted the detention measures on Li Zhe, changing it to a directive for pending investigation [1] - **Background of Li Zhe** - Li Zhe, born in 1986, holds a master's degree and has previously worked as a financial advisor at Sun Life Financial in Montreal, a fund management specialist at Canadian Imperial Bank of Commerce in Toronto, and an investment banking project manager at Guojin Securities in Shanghai [1]

Group 1 - Ruikang Pharmaceutical's executive Li Zhe has had his detention changed to a notice of investigation, indicating a shift in the investigation phase [1] - The change from detention to a notice of investigation suggests a reduced level of coercion, highlighting the importance of internal control and compliance systems in listed companies [1] Group 2 - Zhixiang Jintai has initiated a Phase III clinical trial for GR1802 injection for allergic rhinitis, following communication with the National Medical Products Administration [2] - GR1802 is slightly behind in clinical progress compared to two other approved drugs targeting the same indication, but successful commercialization could lead to competition with Dupilumab [2] Group 3 - Rongchang Biopharmaceutical's innovative drug RC18 (Taitaxip) for primary Sjögren's syndrome has met its primary endpoint in Phase III clinical trials, marking a potential first in the global market for this indication [3] - If approved, this drug could provide a breakthrough treatment for millions of patients in China and strengthen Rongchang's position in the autoimmune field [3] Group 4 - Hengrui Medicine's SHR-A2102, a targeted antibody-drug conjugate (ADC) for Nectin-4, has received approval for clinical trials in combination with Atezolizumab for recurrent/metastatic head and neck squamous cell carcinoma [4] - There is currently only one similar product on the market, Padcev, which is projected to generate $1.949 billion in sales in 2024, indicating significant market potential for this target [4] Group 5 - BeiGene has launched the first domestic Phase III clinical trial for subcutaneous Tislelizumab, a PD-1 inhibitor, for use in combination with chemotherapy for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma [5] - The subcutaneous formulation is becoming a competitive area for PD-1/PD-L1 inhibitors, with three other subcutaneous PD-1/L1 products already approved globally [5]

Group 1 - Kaizhong Precision plans to invest up to 250 million yuan to establish a subsidiary and build a production base in Thailand, focusing on overseas connector and precision component business [1] - Longbo Technology reported a 60.18% year-on-year increase in net profit for the first half of 2025, with revenue of 122 million yuan, up 18.03% [2] - Dingyang Technology achieved a net profit of 76.88 million yuan in the first half of 2025, a year-on-year increase of 31.54%, with revenue of 279 million yuan, up 24.61% [4] Group 2 - Heng Rui Pharmaceutical received approval for clinical trials of two drugs, SHR-A2102 and Adebeli monoclonal antibody injection [6] - Maolai Optical plans to use up to 100 million yuan of idle funds for entrusted wealth management to improve fund utilization efficiency [8] - Shiji Information signed a major contract with MGM Grand, providing a next-generation cloud-based hotel information management system [7] Group 3 - Yunnan Germanium's subsidiary received a government subsidy of 6.8 million yuan related to revenue [9] - Jizhi Co. received a warning letter from the Zhejiang Securities Regulatory Bureau for failing to disclose significant government subsidies [10] - Dongfang Precision reported a net profit of approximately 397 million yuan for the first half of 2025, a year-on-year increase of 142.52% [11] Group 4 - Aolaide expects a net profit decrease of 68.41% to 72.77% for the first half of 2025, with revenue projected between 270 million and 290 million yuan [12] - Feilong Co. used 111 million yuan of idle funds for cash management through structured deposit products [13] - Anhui Construction won two major projects with a total investment exceeding 6.6 billion yuan [15] Group 5 - Yunnan Germanium's subsidiary received a government subsidy of 6.8 million yuan related to revenue [9] - Jizhi Co. received a warning letter from the Zhejiang Securities Regulatory Bureau for failing to disclose significant government subsidies [10] - Dongfang Precision reported a net profit of approximately 397 million yuan for the first half of 2025, a year-on-year increase of 142.52% [11] Group 6 - China Medical's subsidiary received approval for the listing of fumaric acid volnora raw materials [20] - Huayuan Vaccine's subsidiary received approval for clinical trials of Hib vaccine [29] - Ganfeng Lithium plans to integrate lithium salt lake projects in Argentina and provide financial support of up to 130 million USD [41]